Therapeutic targets in dry eye syndrome

Drug News and Perspectives

Volumn 21, Issue 3, 2008, Pages 166-176

  Peral, Assumpta ^a   Domínguez Godínez, Carmen O ^a   Carracedo, Gonzalo ^a   Pintor, Jesús ^a  

^a Escuela Universitaria de Optica   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

12 SULFODEHYDROABIETIC ACID; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALTY 0501; ANTIINFLAMMATORY AGENT; ARTIFICIAL TEAR; BION; CATIONORM; CEVIMELINE; CORTICOSTEROID; CYCLOSPORIN A; DIQUAFOSOL; DOXYCYCLINE; DOXYCYCLINE HYCLATE; DURAMYCIN; ENDURA; FLUOROMETHOLONE; GAMMA LINOLENIC ACID; GEFARNATE; GENTEAL; HYPOTEARS; HYPOTEARS PF; IDESTRIN; LINOLEIC ACID; LOTEPREDNOL ETABONATE; METHOTREXATE; MINOCYCLINE; NOVA 23006; NP 50301; OPTIVE; PILOCARPINE; PIMECROLIMUS; PLACEBO; PROLACRIA; REBAMIPIDE; REFRESH; REFRESH FREE; REFRESH TEARS; RIMEXOLONE; RIVOGLITAZONE; SOOTHE; SYSTANE; TACROLIMUS; TEARS NATURAL FREE; TETRACYCLINE; THERA TEARS; UNINDEXED DRUG; VELOX;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BLEPHARITIS; BLURRED VISION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTACT LENS; DISEASE SEVERITY; DRY EYE; EYE DISEASE; HUMAN; LACRIMAL GLAND; LACRIMATION; LENS IMPLANT; MONOTHERAPY; NONHUMAN; REVIEW; ROSACEA; SCHIRMER TEST; SIDE EFFECT; SJOEGREN SYNDROME; SPECTACLES; SWEATING; SYMPTOMATOLOGY; TEAR FILM; TEAR FLOW; UNSPECIFIED SIDE EFFECT; UVEITIS; XEROPHTHALMIA;

ANTI-INFLAMMATORY AGENTS; DRY EYE SYNDROMES; HUMANS; OPHTHALMIC SOLUTIONS; TEARS;

EID: 44949103301     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2008.21.3.1203413     Document Type: Review

References (97)

1. Research in dry eye: report of the Research Subcommittee of the International Dry Eye WorkShop. Ocul Surf 2007, 5(2): 179-93.
2. Tomlinson, A., Khanal, S., Ramaesh, K. et al. Tear film osmolality: Determination of a referent for dry eye diagnosis. Invest Ophthalmol Vis Sci 2006, 47(10): 4309-15.
3. Schein, O.D., Muñoz, B., Tielsch, J.M. et al. Prevalence of dry eye among the elderly. Am J Ophthalmol 1997, 124(6): 723-8.
4. Lin, P.Y., Tsai, S.Y., Cheng, C.Y. et al. Prevalence of dry eye among an elderly Chinese population in Taiwan: The Shihpai Eye Study. Ophthalmology 2003, 110(6): 1096-101.
5. Murube, J., Nemeth, J., Hoh, H. et al. The triple classification of dry eye for practical clinical use. Eur J Ophthalmol 2005, 15(6): 660-7.
6. Behrens, A., Doyle, J.J., Stern, L. et al. Dysfunctional tear syndrome: A Delphi approach to treatment recommendations. Cornea 2006, 25(8): 900-7.
7. Pflugfelder, S.C., Solomon, A., Stern, M.E. The diagnosis and management of dry eye: a twenty-five-year review. Cornea 2000, 19(5): 644-9.
8. Glasson, M.J., Stapleton, F., Keay, L. et al. The effect of short term contact lens wear on the tear film and ocular surface characteristics of tolerant and intolerant wearers. Cont Lens Anterior Eye 2006, 29(1): 41-7.
9. Glasson, M.J., Stapleton, F., Keay, L. et al. Differences in clinical parameters and tear film of tolerant and intolerant contact lens wearers. Invest Ophthalmol Vis Sci 2003, 44(12): 5116-24.
10. Nichols, K.K., Mitchell, G.L. and Zadnik, K. The repeatability of clinical measurements of dry eye. Cornea 2004, 23: 272-85.
11. Methodologies to diagnose and monitor dry eye disease. 2007 Report of the International Dry Eye Workshop. The Ocular Surface 2007, 5(2): 108-23.
12. McMonnies, C. Responses to a dry eye questionnaire from a normal population. J Am Optom Assoc 1987, 58: 588-9.
13. Begley, C.B., Caffrey, B., Chalmers, R.L. et al. Use of the dry eye questionnaire to measure the symptoms of ocular irritation in patients with aqueous tear deficient dry eye. Cornea 2002, 21: 664-70.
14. Bron, A. J., Evans, V.E. and Smith, J.A. Grading of corneal and conjunctival staining in the context of the other dry eye tests. Cornea 2003, 22(7): 640-50.
15. Berntsen, D.A., Mitchell, G.L. and Nichols, J.J. Reability of grading lissamine green conjunctival staining. Cornea 2006, 25(6): 695-700.
16. Tomlinson, A., Blades, K.J. and Pearce, E.I. What does the phenol red thread test actually measure? Optom Vis Sci 2001, 78(3): 142-6.
17. Occhipinti, J.R., Mosier, M.A., LaMotte, J. et al. Fluorophotometric measurement of human tear turnover rate. Curr Eye Res 1988, 7(10): 995-1000.
18. Pintor, J., Carracedo, G. and Alonso, M.C. Presence of diadenosine polyphosphates in human tears. Pflügers Arch-Eur J Physiol 2002, 3: 432-6.
19. Peral A., Carracedo, J.G., Acosta et al. Increased Levels of Diadenosine Polyphosphates in Dry Eye. Invest Ophthalmol Vis Sci 2006, 47(9): 4053-8.
20. Peral Cerda, M.A., Carracedo Rodriguez, J.G. and Pintor Just, J.J. (Universidad Complutense de Madrid). Method for diagnosing and monitoring the effectiveness of dry-eye treatment. WO 2007128851. November 15, 2007.
21. Peral, A. and Pintor, J. Ocular mucin visualization by confocal laser scanning microscopy. Cornea 2008, in press.
22. González-García, M.J., González-Sáiz, A. and de la Fuente B. Exposure to a controlled adverse environment impairs the ocular surface of subjects with minimally symptomatic dry eye. Invest Ophthalmol Vis Sci 2007, 48(9): 4026-32.
23. Perrigan, D.M., Morgan, A., Quintero, S. et al. Comparison of osmolarity values of selected ocular lubricants. ARVO 2004, poster session 449.
24. Albietz, J. and Bruce, A. The conjunctival epithelium in dry eye subtypes: Effect of preserved and nonpreserved topical treatments. Curr Eye Res 2001, 22(1): 8-18.
25. Smith, L., George, M., Berdy, G. et al. Comparative effects of preservative free tear substitutes on the rabbit cornea: A scanning electron microscopic evaluation (ARVO abstract). Invest Ophthalmol Vis Sci 1991, 32(Suppl.): 733.
26. Nelson, J.D. and Gordon, J.F. Topical fibronectin in the treatment of keratoconjunctivitis sicca. Chiron Keratoconjunctivitis Sicca Study Group. Am J Ophthalmol 1992, 114(4): 441-7.
27. Luo, L., Li, D., Corrales, R. et al. Hyperosmolar saline is aproinflammatory stress on the mouse ocular surface. Eye Contact Lens 2005, 31(5): 186-93.
28. Luo, L., Li, D.Q., Doshi, A. et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci 2004, 45(12): 4293-301.
29. Johnson, M.E. and Murphy, P.J. Changes in the tear film and ocular surface from dry eye syndrome. Progr Retin Eye Res 2004, 23(4): 449-74.
30. Ta, C.N., Shine, W.E., McCulley, J.P. et al. Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Cornea 2003, 22(6): 545-8.
31. Solomon, A., Rosenblatt, M., Li, D.Q. et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Invest Ophthalmol Vis Sci 2000, 41(9): 2544-57.
32. Tamargo, R.J., Bok, R.A. and Brem, H. Angiogenesis inhibition by minocycline. Cancer Res 1991, 51(2): 672-5.
33. Macdonald, A. and Feiwel, M. Perioral dermatitis: Aetiology and treatment with tetracycline. Br J Dermatol 1972, 87(4): 315-9.
34. Jansen, T. and Plewig, G. Rosacea: Classification and treatment. J R Soc Med 1997, 90(3): 144-50.
35. Dougherty, J.M., McCulley, J.P., Silvany, R.E. et al. The role of tetracycline in chronic blepharitis. Invest Ophthalmol Vis Sci 1991, 32(11): 2970-5.
36. Alacrity Biosciences announces positive results from a phase 2 study of its dry eye treatment ALTY-0501 [news release]. Laguna Hills: Alacrity Biosciences; October 9, 2007. http://www.alacritybio.com/pdf/ ALTY0501%20news%20release%20FINAL.pdf. Accessed March 10, 2008.
37. SmartPLUG™ - The intelligent solution for dry eyes. Medennium Web site. http://www.medennium.com/prof_smartplug.htm. Accessed March 10, 2008.
38. Baxter, S.A. and Laibson, P.R. Punctal plugs in the management of dry eyes. Ocul Surf 2004, 2(4): 255-65.
39. Paulsen, F. The human lacrimal glands. Adv Anat Embryol Cell Biol 2003, 170: III-XI, 1-106.
40. Yen, M.T., Pflugfelder, S.C. and Feuer, W.J. The effect of punctal occlusion on tear production, tear clearance, and ocular surface sensation in normal subjects. Am J Ophthalmol 2001, 131(3): 314-23.
41. Korb, D.R., Greiner, J.V., Glonek, T. et al. Effect of periocular humidity on the tear film lipid layer. Cornea 1996, 15(2): 129-34.
42. Tsubota, K., Yamada, M. and Urayama, K. Spectacle side panels and moist inserts for the treatment of dry-eye patients. Cornea 1994, 13(3): 197-201.
43. Pullum, K.W., Whiting, M.A. and Buckley, R.J. Scleral contact lenses: The expanding role. Cornea 2005, 24(3): 269-77.
44. Romero-Rangel, T., Stavrou, P., Cotter, J. et al. Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol 2000, 130(1): 25-32.
45. Rosenthal, P., Cotter, J.M. and Baum, J. Treatment of persistent corneal epithelial defect with extended wear of a fluid-ventilated gas-permeable scleral contact lens. Am J Ophthalmol 2000, 130(1): 33-41.
46. Tauber, J., Davitt, W.F., Bokosky, J.E. et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 2004, 23(8): 784-92
47. Fujihara, T., Murakami, T., Fujita, H. et al. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci 2001, 42(1): 96-100
48. Moli1901 Dry Eye Studies. Lantibio, Inc. Web site. http://www.lantibio.com/Moli_dryEyeStudies.htm. Accessed March 10, 2008.
49. Urashima, H., Okamoto, T., Takeji, Y. et al. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea 2004, 23(6): 613-9.
50. Donshik, P.C., Foulks, G., Monica, M. et al. Multicenter, randomized, double-masked, dose-response, placebo-controlled, parallel-group study of the safety and efficacy of rebamipide (OPC-12759) sterile ophthalmic suspension in the treatment of dry eye. Invest Ophthalmol Vis Sci 2005, 46: E-Abstract 2037.
51. Nakamura, M., Endo, K., Nakata, K. and Hamano, T. Gefarnate increases PAS positive cell density in rabbit conjunctiva. Br J Ophthalmol 1998, 82(11): 1320-3.
52. ISTA Pharmaceuticals announces positive preliminary results from ecabet sodium phase IIb study [news release]. Irvine: ISTA Pharmaceuticals, Inc.; May 31, 2007. http://phx.corporate-ir.net/phoenix.zhtml?c=121179&p= irol-newsArticle&ID=1009801&highlight=. Accessed March 10, 2008.
53. Alcon's fourth quarter sales rise 10.7 percent [news release]. Hunenberg, Switzerland: Alcon, Inc. February 8, 2006 http://invest.alconinc.com/ phoenix.zhtml?c=130946&p=irol-newsArchiveArticle&ID=814685& highlight=. Accessed March 10, 2008.
54. Papas, A.S., Sherrer, Y.S., Charney, M. et al. Successful treatment of dry mouth and dry eye symptoms in Sjögren's syndrome patients with oral pilocarpine: A randomized, placebo-controlled, dose-adjustment study. J Clin Rheumatol 2004, 10(4): 169-77.
55. Aragona, P., Di Pietro, R., Spinella, R. and Mobrici, M. Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjögren's syndrome. Br J Ophthalmol 2006, 90(2): 166-70.
56. Ono, M., Takamura, E., Shinozaki, K. et al. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: A randomized, double-blind clinical study. Am J Ophthalmol 2004, 138(1): 6-17.
57. Petrone, D., Condemi, J.J., Fife, R. et al. Double-blind randomized placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002, 46(3): 748-54
58. Leung, K.C., McMillan, A.S., Wong, M.C., Leung, W.K., Mok, M.Y. and Lau, C.S. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: A randomised double-blind, placebo-controlled crossover study. Clin Rheumatol 2007 Sep 26, Advance publication.
59. Nascent reports positive results for phase II dry eye treatment [news release]. Burlingame: Nascent Pharmaceuticals, Inc.; January 4, 2006. http://www.nascentpharma.com/News11.html. Accessed March 10, 2008.
60. Tsubota, K., Goto, E., Fujita, H. et al. Treatment of dry eye by autologous serum application in Sjögren's syndrome. Br J Ophthalmol 1999, 83(4): 390-5.
61. Geerling, G. and Hartwig, D. Autologous serum eyedrops for ocular surface disorders. In: Cornea and External Eye Disease. Reinhard, T., Larkin, F. (Eds.). Spinger: Berlin, Heidelberg 2005, 2-19.
62. Liu, L., Hartwig, D., Harloff, S. et al. An optimised protocol for the production of autologous serum eyedrops. Graefes Arch Clin Exp Ophthalmol 2005, 243(7): 706-14.
63. Noda-Tsuruya, T., Asano-Kato, N., Toda, I. et al. Autologous serum eye drops for dry eye after LASIK. J Refract Surg 2006, 22(1): 61-6.
64. Geerling, G., Honnicke, K., Schroder, C. et al. Quality of salivary tears following autologous submandibular gland transplantation for severe dry eye. Graefes Arch Clin Exp Ophthalmol 2000, 238(1): 45-52.
65. Barabino, S., Rolando, M., Camicione, P. et al. Systemic linoleic and gammalinolenic acid therapy in dry eye syndrome with an infl ammatory component. Cornea 2003, 22(2): 97-101.
66. Bartels, S.P. (Bausch & Lomb Inc.). Use of loteprednol etabonate for the treatment of dry eye. WO 2005094836. October 13, 2005.
67. Xia, E., Hu, Z., Tyle, P. and Bartels, S. (Bausch & Lomb Inc.). Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy. WO 2006073786. July 13, 2006.
68. Ousler, G.W., Chapin, M.J. and Abelson, M.B. (Ophthalmic Research Associates, Inc.). Formulations and methods for treating dry eye. WO 2007087609. August 2, 2007.
69. Gamache, D.A. (Alcon, Inc.). Use of cytokine synthesis inhibitors for the treatment of dry eye disorders. WO 2004026406. April 1, 2004.
70. Mee, C., Barnett, G. and Coy, M. (Nascent Pharmaceuticals, Inc.). Combination therapy for topical application in the treatment of dry eye syndrome. WO 2006094028. September 8, 2006.
71. Lubkin, V. Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application. US 6096733. August 1, 2000.
72. Toshihiko, V., Shimamura, I., Yorii, H., Ohashi, Y., Shimizu, D., Nishihara, M. (Eisai Co., Ltd.). Agent for treating dry eye. JP8133967. May 28, 1996.
73. Ishii, Y., Itoh, S., Kita, K. and Mukai, K. Composition for prophylaxis and/or treatment of dry eye syndrome comprising vitamin D. US 2001027188. October 4, 2001.
74. Cowlen, M.S., Zhang, V.Z., Warnock, L. et al. Localization of ocular P2Y2 receptor gene expression by in situ hybridization. Exper Eye Res 2003, 77: 77-84.
75. Park, M.-G. and Kuon, M.-K. (MD BioAlpha Co., Ltd.). Composition having effect on treatment and prevention of dry eye syndrome. WO 2007061200. May 31, 2007.
76. Yerxa, B.R., Jacobus, K.M., Rideout, J.L. and Pendergast, W. (Inspire Pharmaceuticals, Inc.). Method of treating dry eye disease with purinergic receptor agonists. WO 9834593. August 13, 1998.
77. Pintor, J,, Peral, A., Hoyle, C.H. et al. Effects of diadenosine polyphosphates on tear secretion in New Zealand white rabbits. J Pharmacol Exp Ther. 2002, 300(1): 291-7.
78. Coquelet, C. and Latour, E. (Chauvin Lab SA). Use of flavine-adenine-dinucleotide for the preparation of ophthalmic compositions for the treatment of the dry eye. EP0930071. July 21, 1999.
79. Ousler, G.W. III, Chapin, M.J. and Abelson, M.B. (Ophthalmic Research Associates, Inc.). Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions. WO 2007067519. June 14, 2007.
80. Yerxa, B.R., Vittitow, J.L. and Ice, J.C. Jr. (Inspire Pharmaceuticals, Inc.). Method of treating dry eye disease with non-drying antihistamines. WO 2007022541. February 22, 2007.
81. Miller, S.T., Gamache, D.A. and Yanni, J.M. (Alcon Laboratories, Inc.). Methods of use of histamine H2 agonists in treating dry eye. US6274160. August 14, 2001.
82. Yerxa, B., Peterson, W. (Inspire Pharmaceuticals, Inc.). Method of treating dry eye disease with nicotinic acetylcholine receptor agonist. WO 0180844. November 11, 2001.
83. Gamache, D., Miller, S. (Alcon Labs, Inc.; Gamache Daniel A.). The use of nitric oxide generations for the treatment of dry eye disorders. WO9930716. June 24, 1999.
84. Ceddaha, M. (LMD SA). Cysteine for oral administration for dry eye treatment. WO 2002055068. July 18, 2002.
85. Chetoni, P., Burgalassi, S., Saettone, M.F., Giannaccini, B. and Boldrini, E. (Farmigea SpA). Ophthalmic composition containing N-acetylcysteine for the treatment of dry-eye syndrome. WO 2003011249. February 13, 2003.
86. Bakhit, P.G., Graham, R. and Olejnik, O. (Allergan, Inc.). Ophthalmic compositions comprising trefoil factor family peptides. WO 2005009459. February 3, 2005.
87. Tsubota, K. (R-Tech Ueno, Ltd.). Drug composition comprising albumin as active ingredient. US6043213. March 28, 2000.
88. Gamache, D.A., Yanni, J.M. and Van Duzee, B.F. (Alcon, Inc.). Methods for treating dry eye. US2003109509. June 12, 2003.
89. Panjwani, N. (Tufts University). Compositions and uses of a galectin for treatment of dry eye syndrome. WO 2006113311. October 26, 2006.
90. Gamache, D.A. and Yanni, J.M. (Alcon, Inc.). Selective PDE-IV inhibitors are useful for treating dry eye disorders and other disorders requiring the wetting of the eye. US 6872382. March 29, 2005.
91. Klimko, P., Hellberg, M.R. Use of proteasome inhibitors to treat dry eye disorders. US2004180859. September 16, 2004.
92. Yanni, J.M. and Gamache, D.A. (Alcon, Inc.). Use of NF-kappaB inhibitors to treat dry eye disorders. WO 2002095704. November 28, 2002.
93. Ueno, R. (Sucampo Pharma AG). Use of macrolide compounds for the treatment of dry eye. US 7063857. June 20, 2006.
94. Ke, T.-L. and Ke, V. (Alcon, Inc.). Method of treating dry eye disorders using glycosides. US 7223737. May 29, 2007.
95. Salamone, J.C., Xia, E. and Liu, X.M. (Bausch & Lomb Inc.). Polysaccharide and polyol composition for treating dry eye and related methods of manufacture and methods of use. WO 2006127121. November 30, 2006.
96. Kis, G.L. and Babiole Saunier, M. (Novartis AG, Novartis Pharma GmbH). Composition of glycosaminoglycan and a peroxide for the treatment of dry eye. WO 2003011305. February 13, 2003.
97. Hoyle C.H.V., Peral A. and Pintor J. Melatonin potentiates tear secretion induced by diadenosine tetraphosphate in the rabbit. Eur J Pharmacol 2006, 552(1-3): 159-61.